b) a fragment of (a) which has agonistic activity on the hGHRH receptor;

c) a variant of (a) or (b) which has at least 70% sequence identity with (a) or (b) and which has agonistic activity on the hGHRH receptor;

d) a variant of (a) or (b) which is encoded by a DNA sequence which hybridizes to the complement of the native DNA sequence encoding (a) or (b) under moderately stringent conditions and which has agonistic activity on the hGHRH receptor; or

f) a salt or functional derivative of (a), (b), (c) or (d) which has agonistic activity on the hGHRH receptor.

25. Use according to claim 4 or 24, wherein the functional derivative comprises at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.

26. Use according to claim 25, wherein the moiety is a polyethylene glycol (PEG) moiety.

27. Use of an IGF (Insulin-like Growth Factor), for the preparation of a medicament for treatment and/or prevention of Parkinsonism-Plus Syndromes, in particular of Multiple System Atrophy.

28. Use according to claim 27, wherein the IGF is selected from IGF-I or IGF-II.

29. Use according to claims 27 or 28, wherein the medicament further comprises and IGFBP (Insulin-like Growth Factor Binding Protein), for simultaneous, sequential, or separate use.

30. Use according to claim 29, wherein the IGFBP is IGFBP3.

31. Use according to any of claims 27 to 30, wherein the medicament further comprises a substance according to any of claims 1 to 26.

32. Use of an nucleic acid molecule comprising the coding sequence of a substance which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance which stimulates release or potentiates the activity of endogenous hGH for the preparation of a medicament for the treatment and/or prevention of a Parkinsonism-Plus Syndrome, in particular Multiple System Atrophy.

33. The use according to any of the preceding claims, wherein the medicament is administered subcutaneously.

34. The use according to any of claims 1 to 32, wherein the medicament is administered intramuscularly.

35. Use according to claim any of the preceding claims, wherein the substance is administered with an auto-injector.

36. Use of a vector for inducing and/or enhancing the endogenous production of a substance which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance which stimulates release or potentiates the activity of endogenous hGH for the preparation of a medicament for the treatment and/or prevention of a Parkinsonism-Plus Syndrome, in particular Multiple System Atrophy.

37. Use of a cell that has been genetically modified to produce a substance which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance which stimulates release or potentiates the activity of endogenous hGH for the preparation of a medicament for the treatment and/or prevention of a Parkinsonism-Plus Syndrome, in particular Multiple System Atrophy.

38. A method for treating a Parkinsonism-Plus Syndrome, in particular Multiple System Atrophy, comprising administering to a patient in need thereof an effective amount of a substance which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance which stimulates release or potentiates the activity of endogenous hGH.